medigraphic.com
ISSN 1561-2996 (Electronic)
ISSN 0864-0289 (Print)

2020, Number 4

<< Back Next >>

Rev Cubana Hematol Inmunol Hemoter 2020; 36 (4)

Flow cytometry diagnosis of a patient with chronic lymphocytic leukemia

Triana MY, Marsán SV, Duarte PY

Language: Spanish
References: 23
Page: 1-17
PDF size: 503.54 Kb.


ABSTRACT

Introduction: Flow cytometry is an advanced, objective, highly sensitive technique for the simultaneous analysis and quantification of multiple cellular parameters. This technique is very common in the study of chronic lymphocytic leukemia, a condition defined as a malignant proliferative disorder of mature, incompetent lymphocytes.
Objective: Describe the diagnostic strategy for flow cytometry immunophenotyping of chronic lymphocytic leukemia.
Methods: Flow cytometry testing was performed of a bone marrow sample taken from a patient with clinical and morphological suspicion of chronic lymphocytic leukemia. Cell immunophenotyping was based on monoclonal antibodies targeted against lymphoid differentiation antigens B and T. The sample was read in a GALLIOS Beckman Coulter cytometer, and the data obtained were analyzed with the software Kaluza.
Results: Antigens with a positive expression were CD19 (99.94%), CD20 (81.56%), CD5 (80.25%), as well as the co-expression of CD5+/CD19+ (96.56%), CD5+/CD20+ (80.56%), CD19+/CD20+ (84.86%), CD23 (62.65%), CD49d (65.18%), CD38 (52.17%). Monoclonality of the k light chain was present in 44.27%. Expression of antigens CD3, CD4, CD8 and CD25 was found to be negative.
Conclusions: The diagnostic strategy proposed made it possible to identify the antigens most frequently expressed in patients with chronic lymphocytic leukemia, as well as their co-expression and the monoclonality of the k chain, all of which are cell markers allowing flow cytometry-based immunophenotypical diagnosis of chronic lymphocytic leukemia.


REFERENCES

  1. Triana Marrero Y, Marsán Suárez V, Sánchez Ballester A, Díaz Domínguez G. Leucemia linfoide crónica de células B: revisión de sus aspectos etiopatogénicos, moleculares y pronósticos. Rev Cubana Hematol Inmunol Hemoter. 2019;35(1):e927.

  2. Eichhorst B, Robak T, Montserrat E, Ghia P,Hillmen P, Hallek M, et al. Chronic lymphocyticleukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol.2015;26(5):78-84. DOI: http://10.1093/annonc/mdv303

  3. Martín GP, Puerta JM, Chacón MJ. Leucemia linfática crónica B. Diagnóstico, pronóstico y tratamiento. Actual Med. 2017; 100(800):52-3. DOI: http://10.15568/am.2017.800.ao01

  4. Valdespino-Gómez VM. Leucemia linfocítica crónica de linfocitos B: un modelo personalizado de valoración clínica y molecular. Rev Hematol Mex. 2014;15:103-21.

  5. Arrais RC, Vescovi GV, Valério IRM, Lorand-Metzee I, André Domingues PA, Leão CD, et al. Diagnosis and treatment of chronic lymphocytic leukemia: recommendations from the Brazilian Group of Chronic Lymphocytic Leukemia. Rev Bras Hematol Hemoter. 2016;38(4):34657.

  6. Kipps TJ, Stevenson FK, Wu JC, Croce MC, Packham G, Wierda CW, et al. Chronic lymphocytic leukaemia. Nat Rev Dis Primers.2017; 3:160-96. DOI: http://10.1038/nrdp.2016.96

  7. Sall A, Touré AO, Sall FB, Ndour M, Fall S, Sène A, et al. Characteristics of chronic lymphocytic leukemia in Senegal. BMC Hematol 2016;23;16:10.https://doi.org/10.1186/s12878-016-0051-y

  8. Rai KR, Jain P. Chronic lymphocytic leukemia (CLL)-Then and now. Am J Hematol 2016; 91:330-40.

  9. Pui CH, Behm FG, Crist WM. Clinical and biologic relevance of immunologic marker studies in childhood acute lymphoblastic leukemia. Blood 2013; 82(2):343-62.

  10. Drenon B, Fardel O, Fauchet R, Amiot J. Flow cytometry: application for the diagnosis and the follow-up of hematological malignancies. Ann Biol Clin 2013; 60(6):663-72.

  11. Pagnucco G, Vanelli L, Gervasi F. Multidimensional flow cytometry immuno phenotyping of hematologic malignancy. Ann N Y AcadSci.2013; 963:313-21.

  12. Kussick SJ, Kalnoski M, Braziel RM, Wood BL. Prominent clonal B cell populations identified by flow cytometry in histologically reactive lymphoid proliferations. Am J ClinPathol.2004; 121:464-72.

  13. Sorigue Marc, Juncà,Jordi. Atypical chronic lymphocytic leukemia: Brief historical overview and current us age of anequivocal concept. Int J Lab Hematol. 2019 Feb;41(1):17-19. https://doi.org/10.1111/ijlh.12930

  14. Hallek M, Cheson BD, Catovsky D. Guidelines for the diagnosis and treatment of chronic lymphocyticleukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008; 111:5446-56.

  15. Ivancevic DT, Kurtovic KN, Knezevic V. The Role of Immunophenotyping in Differential Diagnosis of Chronic Lymphocytic Leukemia. Srp Arh Celok Lek. 2014 Mar-Apr;142(3-4):197-203. DOI: http://10.2298/sarh1404197d

  16. Shahni A, Saud M, Siddiqui S, Mukry SN. Expression of aberrant antigens in hematological malignancies: A single center experience. Pak J Med Sci. 2018; 34(2):457-62.

  17. Nieto WG, Almeida J, Romero A, Teodosio C, Lopez A, Henriques AF, et al. Increased frequency (12%) of circulating chronic lymphocytic leukemia-like B-cell clones in healthy subjects using a highly sensitive multicolor ?ow cytometry approach. Blood 2009; 114(1):33-7.

  18. Schroers R, Baraniskin A, Heute C, Kuhnhenn J, Alekseyev A, Schmiegel W, et al. Detection of free immunoglobulin light chains in cerebro spinal fluids of patients with central nervous system lymphomas. Eur J Haematol 2010; 85:236-42.

  19. Eichhorst B. Appendix 6: chronic lymphocytic leukaemia. Ann Oncol. 2016; 27(5):143-4.

  20. International CLL-IPI working group. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data. Lancet Oncol. 2016; 17:779-90.

  21. Haq H, Uddin N, Khan SA, Ghaffar S. Prognostic markers in Chronic Lymphocytic Leukaemia. A flow cytometric analysis. Pak J Med Sci 2020;36(3):338-43.

  22. Eichhorst B, Hallek M. Prognostication of chronic lymphocytic leukemia in the era of new agents. Hematology Am Soc Hematol Educ Program. 2016; (1):149-55.

  23. Popova V, Blazheva S, Lukanov T, Naneva S, Tzvetkov N. Study of the immunological markers CD49d and CD38 in early-stage B-CLL patients. J IMAB. 2018; 24(1):1883-6. DOI: http://10.5272/jimab.2018241.1883




2020     |     www.medigraphic.com